Help us make ribociclib available to more breast cancer patients
Categories: Personal Diagnosis, Hormone Receptor+ve, HER2-ve
What’s the project about?
Ribociclib (also known as Kisqali) is already used for certain patients with secondary breast cancer.
NICE is assessing adjuvant ribociclib when it’s used after surgery for treating hormone receptor positive HER2-negative primary breast cancer. They’re deciding whether to approve it for use on the NHS in England.
We’re looking to hear from people who've received this treatment for primary breast cancer about their experiences of the drug. These responses will help to shape our input into NICE’s appraisal.
Who can take part?
We want to hear from people with hormone receptor positive HER2-negative primary breast cancer, who’ve been treated with ribociclib after surgery.
Why do you want me to be involved?
It’s vital that we include your voices in our NICE submission to ensure that those with lived experience are heard. By sharing your views on why this drug should be made available on the NHS in England, you can help us strengthen our response to the NICE consultation.
What will you ask me to do?
We want you to tell us about your experience taking ribociclib and why you think it’s important that it’s made available on the NHS.
Share your voice
This opportunity has expired. You can check out our Share your voice page for more ways to get involved.